Phase 2 Eating Disorders Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been formally diagnosed with Anorexia Nervosa (AN) based on recognised medical guidelines, confirmed through a structured interview
- Your Body Mass Index (BMI) is above 13 but no higher than 18, and you weigh at least 35 kg (about 77 lbs)
- You are currently admitted as a patient in the Eating Disorders Unit at the University Hospital of Zurich, Switzerland
- You are able to understand and communicate in German
- You are between 17 and 65 years old
- You are experiencing some level of depressive symptoms, as measured by a standard depression rating scale (confirm with trial site)
- If you can become pregnant: you have tested negative for pregnancy, are not breastfeeding, and are using two forms of birth control
- You are willing and able to sign a consent form agreeing to take part
Who may not be able to join:
- You have used illegal drugs in the past month, or you currently have a problem with alcohol use
- You have certain serious mental health or physical health conditions, such as schizophrenia, bipolar disorder, inflammatory bowel disease, diabetes, autoimmune disorders, pancreatitis, neurological conditions, or cancer including lymphoma
- You are currently having thoughts of suicide or are engaging in serious self-harm
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 0041 44 255 52 80
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Clinician-rated depression on the 17 point Hamilton Depression Scale (HAMD-17) in the metreleptin-assisted therapy group compared to placebo-therapy group between Baseline, Post Treatment and 5 weeks Follow Up; Body weight status in the metreleptin-assisted therapy group compared to placebo-therapy group between Baseline, Post Treatment and 5 weeks Follow Up
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.